当前期刊: Best Practice & Research Clinical Rheumatology Go to current issue    加入关注   
显示样式:        排序: IF: - GO 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Diffuse idiopathic skeletal hyperostosis: Etiology and clinical relevance
    Best Pract. Res. Clin. Rheumatol. (IF 3.016) Pub Date : 2020-05-23
    Jonneke S. Kuperus; Firdaus A.A. Mohamed Hoesein; Pim A. de Jong; Jorrit Jan Verlaan

    Diffuse idiopathic skeletal hyperostosis (DISH) is a systemic bone-forming condition characterized by the presence of at least three bony bridges at the anterolateral spine. The aim of this review was to address the present state of pathophysiological knowledge, the clinical relevance, and diagnosis of DISH. The pathogenesis of DISH is currently unknown. The presence of DISH has been associated with

    更新日期:2020-05-23
  • Prevention and adherence in Rheumatic and Musculoskeletal disease.
    Best Pract. Res. Clin. Rheumatol. (IF 3.016) Pub Date : 2020-05-13
    Bente Appel Esbensen,Norelee Kennedy,Nina Brodin

    Rheumatic and Musculoskeletal Diseases (RMDs) are chronic conditions that affect a substantial number of people. RMDs are significantly related to co-morbidity. Therefore, focusing on prevention in RMDs is of importance to promote and maintain health. Prevention includes primary-, secondary-, tertiary-, and clinical prevention. Primary prevention aims to prevent the onset of disease before the disease

    更新日期:2020-05-13
  • Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy.
    Best Pract. Res. Clin. Rheumatol. (IF 3.016) Pub Date : 2020-05-07
    Georgia Griffin,Susan Shenoi,Grant C Hughes

    Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening state of immune hyperactivation that arises in the setting of genetic mutations and infectious, inflammatory, or neoplastic triggers. Sustained, aberrant activation of cytotoxic CD8+ T cells and resultant inflammatory cytokine release are core pathogenic mechanisms. Key clinical features include high persistent fever, hepatosplenomegaly

    更新日期:2020-05-07
  • Microbes, helminths, and rheumatic diseases.
    Best Pract. Res. Clin. Rheumatol. (IF 3.016) Pub Date : 2020-05-07
    Francisco Airton Castro Rocha,Ana Margarida Duarte-Monteiro,Licia Maria Henrique da Mota,Ana Carolina Matias Dinelly Pinto,João Eurico Fonseca

    There has been a progressive interest on modifications of the human defense system following insults occurring in the interface between our body and the external environment, as they may provoke or worsen disease states. Studies suggest that billions of germs, which compose the gut microbiota influence one's innate and adaptive immune responses at the intestinal level, but these microorganisms may

    更新日期:2020-05-07
  • The gut microbiome in psoriasis and psoriatic arthritis.
    Best Pract. Res. Clin. Rheumatol. (IF 3.016) Pub Date : 2020-04-29
    Bridget Myers,Nicholas Brownstone,Vidhatha Reddy,Stephanie Chan,Quinn Thibodeaux,Alexa Truong,Tina Bhutani,Hsin-Wen Chang,Wilson Liao

    This review summarizes existing research on the gut microbiome composition and function in psoriasis and psoriatic arthritis, exploring potential roles in disease pathogenesis, progression, and management. A strong relationship between skin, joint, and gastrointestinal inflammation exists, as demonstrated by an increased prevalence of psoriasis, psoriatic arthritis, and inflammatory bowel disease co-occurring

    更新日期:2020-04-29
  • Primary hyperparathyroidism.
    Best Pract. Res. Clin. Rheumatol. (IF 3.016) Pub Date : 2020-04-23
    Júlia V Oberger Marques,Carolina A Moreira

    Primary hyperparathyroidism (PHPT) is a condition that affects calcium metabolism due to parathyroid hormone (PTH) hypersecretion leading to hypercalcemia. Manifestations have changed over time, from a symptomatic disease with bone pain, fractures, nephrolithiasis, and muscle weakness, to a condition that is mainly asymptomatic (80-90%). Typical symptoms and signs occur in the bones and kidneys and

    更新日期:2020-04-24
  • Methods in microbiome research: Past, present, and future.
    Best Pract. Res. Clin. Rheumatol. (IF 3.016) Pub Date : 2020-04-24
    Emily C Gotschlich,Robert A Colbert,Tejpal Gill

    The human microbiome is impressively immense and participates in many aspects of our health and wellness, particularly involving the development and maintenance of a healthy immune system. Not only do our microbes teach the immune system to fight infection, they also teach immune tolerance and help maintain homeostasis. From this knowledge, we have learned that the loss of tolerance to microbiota in

    更新日期:2020-04-24
  • Uncommon compressive neuropathies of upper limbs.
    Best Pract. Res. Clin. Rheumatol. (IF 3.016) Pub Date : 2020-04-21
    Milton Helfenstein Júnior

    To present the clinical features of less common entrapment neuropathies of upper limbs, introduce diagnostic tools, comment on the general bases of treatment, and create awareness of these conditions. Although these conditions are rare, adequate and rapid diagnosis is necessary to initiate appropriate treatment in a timely manner, in order to avoid further nerve insults, associated muscle atrophy,

    更新日期:2020-04-21
  • Suspected very early inflammatory rheumatic diseases in primary care
    Best Pract. Res. Clin. Rheumatol. (IF 3.016) Pub Date : 2019-07-24
    Louise Warburton; Samantha L. Hider; Christian D. Mallen; Ian C. Scott

    As primary care clinicians are typically the first point of contact for patients with musculoskeletal problems, they are crucial to the early diagnosis and treatment of patients with an incident inflammatory arthritis, like rheumatoid arthritis. Current UK and international guidelines recognise this, recommending the prompt referral of patients with suspected persistent synovitis to secondary care

    更新日期:2020-04-20
  • Preclinical and early systemic lupus erythematosus
    Best Pract. Res. Clin. Rheumatol. (IF 3.016) Pub Date : 2019-07-12
    Mariele Gatto; Francesca Saccon; Margherita Zen; Luca Iaccarino; Andrea Doria

    The challenge of early diagnosis and treatment is a timely issue in the management of systemic lupus erythematosus (SLE), as autoimmunity starts earlier than its clinical manifestations. Hence, growing efforts for stratification of patients according to the individual risk of developing specific clinical manifestations and/or predicting a better response to a given treatmen